No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Lampalizumab is a drug used to treat optical disorders, such as geographic atrophy (GA) and dry age-related macular degeneration (AMD). It is a humanized monoclonal antibody that binds to and inhibits the activity of complement factor D, a key component of the complement system. By inhibiting the activity of complement factor D, lampalizumab reduces the formation of the membrane attack complex, which is responsible for the destruction of photoreceptor cells in the retina.
Lampalizumab is administered as an intravitreal injection, and is currently approved for use in the United States, Europe, and Japan. It is the first and only drug approved for the treatment of GA, and is also used off-label to treat dry AMD.
The lampalizumab market is a rapidly growing segment of the optical disorders drugs market. It is expected to benefit from the increasing prevalence of AMD and GA, as well as the growing demand for effective treatments.
Some of the major companies in the lampalizumab market include Genentech, Novartis, Regeneron Pharmaceuticals, and Roche. Show Less Read more
